Rapt Therapeutics Inc (RAPT) USD0.0001
Sell:$1.14Buy:$1.20
$0.05
(4.10%)
- This stock can be held in a
Stocks and Shares ISA$0.05
(4.10%)$0.05
(4.10%)Company Information
About this company
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
Key people
Key facts
- EPICRAPT
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS75382E1091
- Market cap$161.05m
- Employees68
- Shares in issue132.01m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.